Focal macular electroretinogram in macular edema secondary to central retinal vein occlusion.
ABSTRACT To evaluate the usefulness of focal macular electroretinography (fmERG) for evaluation of macular function in eyes with central retinal vein occlusion (CRVO).
fmERG recordings were made prospectively in 24 patients with unilateral CRVO. The amplitudes and latencies of the a-wave, b-wave, and photopic negative response (PhNR) were compared with other biological parameters, including visual acuity (VA), retinal sensitivity measured with a microperimeter, and optical coherence tomography.
In eyes affected by CRVO, amplitudes of the a-wave, b-wave, and PhNR were reduced significantly, and latencies were prolonged significantly compared with those of healthy fellow eyes (P < 0.001). Relative amplitudes (affected eye/fellow eye) of each wave showed a cross correlation with VA. Furthermore, both relative amplitudes and latencies of each wave tended to correlate with retinal sensitivity within the macular area. Central foveal thickness showed a correlation with both relative amplitude and relative latency. Among all parameters, relative amplitude of the PhNR correlated most strongly with central foveal thickness (r = -0.598, P = 0.0042). In addition, sensory retinal thickness showed a correlation with relative latencies, and height of the retinal detachment (when present) showed a correlation with relative amplitudes. In ischemic CRVO, relative amplitudes were reduced more severely than were those in nonischemic CRVO.
In eyes with CRVO, amplitudes and latencies of the fmERG correlated with other biological parameters. Based on the present study, fmERG appears to be useful for the examination of the macular edema that accompanies CRVO.
- [show abstract] [hide abstract]
ABSTRACT: OBJECTIVE: To investigate the potential of optical coherence tomography (OCT) and photopic negative response (PhNR) for predicting visual outcome after intravitreal bevacizumab in patients with macular edema secondary to central retinal vein occlusion (CRVO). METHODS: Thirty-two consecutive patients with macular edema secondary to unilateral CRVO who were treated with three times of 6 weeks interval intravitreal bevacizumab were enrolled. LogMAR visual acuity (Va), OCT and PhNR were done before and 4 weeks after first and third injection. Stepwise multiple regression analysis was conducted between pre-treatment Va, central retinal thickness, b wave amplitude, PhNR amplitude, PhNR relative amplitude (affected eye/unaffected fellow eye, % presentation) and post-treatment Va at 4 weeks after the third injection. The predictive values of pre-treatment parameters for good visual outcome (0.2 ≤ LogMAR Va) were assessed using receiver-operating characteristics (ROC) analysis. RESULTS: In multiple regression analysis, pre-treatment Va (β = 0.615, P = 0.001) and PhNR relative amplitude (β = -0.352, P = 0.032) were correlated significantly with post-treatment Va. In ROC analysis, pre-treatment Va showed a 80 % sensitivity and 80 % specificity for predicting good visual outcome, at a cutoff value of 0.52 LogMAR. Pre-treatment PhNR relative amplitude demonstrated a 88 % sensitivity and 75 % specificity for predicting good visual outcome, at a cutoff value of 40.00 %. CONCLUSIONS: The PhNR relative amplitude can be a useful prognostic factor for visual outcome after intravitreal bevacizumab therapy in patient with macular edema secondary to CRVO. Patients with larger pre-treatment PhNR relative amplitude with better pre-treatment Va showed a better post-treatment visual outcome.Documenta Ophthalmologica 03/2013; · 1.54 Impact Factor
- 08/2011; , ISBN: 978-953-307-383-5
- [show abstract] [hide abstract]
ABSTRACT: Objective. To compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical retinopathy and healthy subjects. Materials and Methods. Optical coherence tomography (OCT) measurements were performed in 124 eyes of 62 subjects with diabetes mellitus without clinical retinopathy (study group: 39 females, 23 males; mean age: 55.06 ± 9.77 years) and in 120 eyes of 60 healthy subjects (control group: 35 females, 25 males; mean age: 55.78 ± 10.34 years). Blood biochemistry parameters were analyzed in all cases. The data for central macular thickness (at 1 mm), the levels of fasting plasma glucose, and glycosylated hemoglobin (HbA1c) were compared in both groups. Results. The mean central macular thickness was 232.12 ± 24.41 µm in the study group and 227.19 ± 29.94 µm in the control group. The mean HbA1c level was 8.92 ± 2.58% in the study group and 5.07 ± 0.70% in the control group (P = 0.001). No statistically significant relationship was found between CMT, HbA1c, and fasting plasma glucose level in either group (P > 0.05). Conclusions. Central macular thickness was not significantly thicker in patients with type 2 diabetes without clinical retinopathy than in healthy subjects.Journal of Ophthalmology 01/2013; 2013:767931. · 1.37 Impact Factor